CymaBay Therapeutics, Inc.
CBAY · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $31 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $31 | -$0 |
| % Margin | 1.8% | – | 99.3% | – |
| R&D Expenses | $23 | $20 | $20 | $19 |
| G&A Expenses | $20 | $12 | $12 | $8 |
| SG&A Expenses | $20 | $12 | $12 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | $0 | $0 |
| Operating Expenses | $42 | $32 | $31 | $27 |
| Operating Income | -$42 | -$32 | -$0 | -$27 |
| % Margin | -74,557.9% | – | -0.3% | – |
| Other Income/Exp. Net | $1 | -$2 | -$1 | -$2 |
| Pre-Tax Income | -$42 | -$34 | -$1 | -$29 |
| Tax Expense | $0 | $0 | $0 | $6 |
| Net Income | -$42 | -$34 | -$1 | -$35 |
| % Margin | -73,512.3% | – | -2.6% | – |
| EPS | -0.37 | -0.32 | -0.008 | -0.36 |
| % Growth | -15.6% | -3,950.6% | 97.8% | – |
| EPS Diluted | -0.37 | -0.32 | -0.008 | -0.36 |
| Weighted Avg Shares Out | 113 | 106 | 102 | 98 |
| Weighted Avg Shares Out Dil | 113 | 106 | 102 | 98 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $3 | $3 | $2 |
| Interest Expense | $5 | $5 | $5 | $4 |
| Depreciation & Amortization | $0 | $0 | $0 | $3 |
| EBITDA | -$37 | -$39 | $4 | -$24 |
| % Margin | -64,500% | – | 13% | – |